

confidence intervals (CIs) for the prevalence of concurrent cancer (within three months of endometrial hyperplasia diagnosis), or the incidence of cancer, identified at least three months after hyperplasia diagnosis.

**Results** A total of 36 articles were identified; 15 investigating concurrent and 21 progression to cancer. In pooled analysis of 11 studies of atypical hyperplasia, the pooled prevalence of concurrent endometrial cancer was 33.4% (95% CI: 26.1%, 42.8%) while no studies evaluated concurrent cancer prevalence in non-atypical hyperplasia. The risk of progression to cancer was high in atypical hyperplasia (n=5 studies, pooled annual incidence rate=8.2%, 95% CI 3.9%, 17.3%) and only one study reported on progression to cancer in non-atypical hyperplasia (annual incidence rate=2.6%, 95% CI: 0.6%, 10.6%), see figure 1.

**Conclusions** Over a third of women with atypical hyperplasia had concurrent endometrial cancer, although the number of studies, especially population-based, is small. Progression to cancer in atypical hyperplasia was high, but few studies were identified. Population-based estimates are required, in both atypical and non-atypical hyperplasia patients, to better inform treatment strategies.

## IGCS19-0342

### 349 PREVALENCE OF POLYPS AND ENDOMETRIAL CANCER IN A PUBLIC HOSPITAL IN BRAZIL

L Resende\*. Hospital de Base – DF, Gynecology Oncology, Brasília, Brazil

10.1136/ijgc-2019-IGCS.349

**Objectives** Classify the epidemiological profile of patients with endometrial pathologies treated in a public hospital in Brazil.

**Methods** During two years patients with endometrial pathologies were referred to the gynecologic oncology clinic of a public hospital in Brasilia - DF, Brazil. Patients were referred by presenting: endometrial thickening, bleeding in postmenopausal period, abnormal bleeding, and completed a clinical and epidemiological questionnaire. During the examination was drawn sample for biopsy when any abnormality was found.

**Results** 216 patients were selected e undergone to hysteroscopic exam.60 (27.8%) had visible changes and underwent biopsy. The specimens were classified according to WHO guidelines and found: 26 (43,2%) polyps; 4 (6,7%) submucosal myoma; 12 (20%) simple hyperplasia; 4 (6,7%) simple atypical hyperplasia; 6 (10%) complex hyperplasia; 4 (6,7%) complex atypical hyperplasia and 4 (6,7%) adenocarcinoma. Mean age 52,3 years; BMI 27,7 kg/m2; mean range thickness 14,1 mm. 4 cases of adenocarcinoma with endometrial thickened above the average.

**Conclusions** Endometrial cancer is more prevalent in older women, in particular, over 50 years, which makes worse the picture is even more to know that the life expectancy of the Brazilian increased, significantly in recent decades. Among women it raises from 69.8 years in 1991 to 78.3 years in 2012, almost 10 years. The availability in the public service of a greater number of hysteroscopy devices associated with endometrial biopsies could increase the number of patients diagnosed with endometrial cancer in women with symptoms or oligosymptomatic and, therefore,

treatment in the initial phase of the disease presents better average survival results.

## IGCS19-0077

### 350 THE LOW RISK OF CIN2+ IN TRIAGE NEGATIVE HPV-POSITIVE WOMEN 5 YEARS AFTER PRIMARY SCREENING

<sup>1</sup>G Stanczuk\*, <sup>2</sup>K Cuschieri, <sup>3</sup>T Palmer. <sup>1</sup>Western Isles Hospital- NHS Scotland-UK, Obstetrics and Gynaecology, Stornoway, UK; <sup>2</sup>Scottish HPV Reference Laboratory-, Royal Infirmary of Edinburgh, Edinburgh, UK; <sup>3</sup>Raigmore Hospital, Department of Pathology, Inverness, UK

10.1136/ijgc-2019-IGCS.350

**Objectives** The optimal triage of screen-positive women is one of the most important considerations in the HPV cervical screening. Performing liquid based cytology (LBC) on HPV-positive (HPV+) women and/or limited genotyping has been recommended as a triage strategy. Additionally p16/ki-67 dual-stained cytology is a credible triage approach. We previously reported an evaluation of triage strategies in a cross sectional study. The aim of this study was to evaluate the cumulative incidence rate (CIR) of CIN2+ within 5 years of primary triage strategies of HPV+ women.

**Methods** The study population comprised of 385 HPV+ women, who all had HPV 16/18 typing, LBC and p16/ki-67 dual-stained cytology at the first screening round. We used two rounds screening results to describe cumulative incidence rate (CIR) of CIN2+ within 5 years of primary HPV+ testing stratified by the various triage strategies with proportions reflected within 95% confidence intervals.

**Results** The length of follow-up was up to 5.5 years. The HPV+ women with an LBC negative triage had 5-year CIR of CIN2+of 9.4%(6.5–13.3%) compared with 7.2% (4.6–11.1%) in women who were p16/ki-67 dual-stained cytology negative and 10.6% (7.5–15%) in women who were HVP 16/18 negative. Regarding combination approaches, HPV 16/18 negative/LBC negative women had 5-year CIR of CIN2+of 3.9% (2.0–7.6%). Women who were “triple” triage negative had the lowest CIR of CIN2+ of 2.4% (0.9–6.0%).

**Conclusions** Full analysis will be presented however; our initial data indicate that multistep triage options may offer the greatest longitudinal protection for concurrent and subsequent disease compare to individual approaches.

## IGCS19-0097

### 351 A NEW SCORING SYSTEM FOR COLPOSCOPY FOR DETECTION CERVICAL INTRAEPITHELIAL NEOPLASIA 2+

<sup>1,2</sup>V Villoslada Terrones\*, <sup>3</sup>C Acosta Cortez, <sup>4</sup>B Fora Chura, <sup>1</sup>M Alvarez Larraondo. <sup>1</sup>National institute of neoplastic diseases- Lima- Perú, Gynecological Surgery, Lima, Peru; <sup>2</sup>National University of Cajamarca, Data analyst- visiting professor and researcher of the School of Human Medicine, Cajamarca, Peru; <sup>3</sup>National University Agraria la Molina, statistic, lima, Peru; <sup>4</sup>Hipolito Unanue Hospital, Obstetrics and Gynecology, Tacna, Peru

10.1136/ijgc-2019-IGCS.351

**Objectives** To construct scoring for colposcopic examination that can better prediction for detection CIN 2+.